UNASSIGNED: We retrospectively enrolled patients who underwent reconstruction surgery between April 2014 to March 2022. eGFR was measured pre- and postoperatively. The \'static renal function\' was defined as a change in eGFR of 20% or less at the last follow-up, and the \'worsening renal function group\' was defined as a decrease of greater than 20%.
UNASSIGNED: A total of 61 SK patients were involved. The success rate of ureteral reconstruction surgery was 90.16% (55/61). The median follow-up time was 20.8 months (range, 3.7-109.2 months). The median eGFR was 65.5 (range, 15.1-99.9) and 65.3 (range, 3.8-123.4) mL/min/1.73 m2 at the baseline and the last follow-up. No statistically significant difference in eGFR was observed between the preoperative baseline and last follow-up visits (P=0.58). However, in patients with baseline renal dysfunction [chronic kidney disease (CKD) stage 3-5], the eGFR significantly improved at the last follow-up compared to the baseline (P=0.02). Three patients developed a \'worsening renal function\' (4.92%). Besides, the systolic blood pressures (SBP) at follow-up significantly reduced compared to the preoperative baseline (P=0.002).
UNASSIGNED: Ureteral reconstruction surgery is an effective treatment to preserve renal function, which also achieves a high success rate and is associated with the reduction of SBP for SK patients with US.
■我们回顾性纳入2014年4月至2022年3月期间接受重建手术的患者。术前和术后测量eGFR。“静态肾功能”定义为在最后一次随访时eGFR的变化为20%或更小,肾功能恶化组定义为下降超过20%。
■共纳入61例SK患者。输尿管重建手术成功率为90.16%(55/61)。中位随访时间为20.8个月(范围,3.7-109.2个月)。eGFR中位数为65.5(范围,15.1-99.9)和65.3(范围,在基线和最后一次随访时,3.8-123.4)mL/min/1.73m2。术前基线和末次随访之间的eGFR差异无统计学意义(P=0.58)。然而,在基线肾功能不全[慢性肾脏病(CKD)3-5期]的患者中,与基线相比,末次随访时eGFR显著改善(P=0.02).三名患者出现“肾功能恶化”(4.92%)。此外,随访时收缩压(SBP)较术前基线显著降低(P=0.002).
■输尿管重建手术是保护肾功能的有效治疗方法,这也获得了很高的成功率,并且与US患者的SBP降低有关。